A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups

BackgroundPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover,...

Full description

Bibliographic Details
Main Authors: Yuting Gao, Li Wei, Seok Jin Kim, Liang Wang, Yingzhi He, Yanfang Zheng, Luca Bertero, Alessia Pellerino, Paola Cassoni, Luca Tamagnone, Prochazka Katharina Theresa, Alexander Deutsch, Huien Zhan, Jing Lai, Yao Wang, Hua You
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.696147/full
id doaj-500e366c639d45f688f61bc4f369c0cd
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Yuting Gao
Li Wei
Li Wei
Seok Jin Kim
Liang Wang
Yingzhi He
Yanfang Zheng
Yanfang Zheng
Luca Bertero
Alessia Pellerino
Paola Cassoni
Luca Tamagnone
Luca Tamagnone
Prochazka Katharina Theresa
Alexander Deutsch
Huien Zhan
Jing Lai
Yao Wang
Hua You
spellingShingle Yuting Gao
Li Wei
Li Wei
Seok Jin Kim
Liang Wang
Yingzhi He
Yanfang Zheng
Yanfang Zheng
Luca Bertero
Alessia Pellerino
Paola Cassoni
Luca Tamagnone
Luca Tamagnone
Prochazka Katharina Theresa
Alexander Deutsch
Huien Zhan
Jing Lai
Yao Wang
Hua You
A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
Frontiers in Oncology
primary central nervous system lymphoma
lactate dehydrogenase-to-lymphocyte ratio
prognostic parameter
Memorial Sloan Kettering Cancer Center (MSKCC) score
neutrophil-to-lymphocyte ratio
author_facet Yuting Gao
Li Wei
Li Wei
Seok Jin Kim
Liang Wang
Yingzhi He
Yanfang Zheng
Yanfang Zheng
Luca Bertero
Alessia Pellerino
Paola Cassoni
Luca Tamagnone
Luca Tamagnone
Prochazka Katharina Theresa
Alexander Deutsch
Huien Zhan
Jing Lai
Yao Wang
Hua You
author_sort Yuting Gao
title A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
title_short A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
title_full A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
title_fullStr A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
title_full_unstemmed A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
title_sort novel prognostic marker for primary cns lymphoma: lactate dehydrogenase-to-lymphocyte ratio improves stratification of patients within the low and intermediate mskcc risk groups
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-08-01
description BackgroundPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL.MethodsWe included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort.ResultsBy univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system.ConclusionsIn the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model.
topic primary central nervous system lymphoma
lactate dehydrogenase-to-lymphocyte ratio
prognostic parameter
Memorial Sloan Kettering Cancer Center (MSKCC) score
neutrophil-to-lymphocyte ratio
url https://www.frontiersin.org/articles/10.3389/fonc.2021.696147/full
work_keys_str_mv AT yutinggao anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT liwei anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT liwei anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT seokjinkim anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT liangwang anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT yingzhihe anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT yanfangzheng anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT yanfangzheng anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT lucabertero anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT alessiapellerino anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT paolacassoni anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT lucatamagnone anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT lucatamagnone anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT prochazkakatharinatheresa anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT alexanderdeutsch anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT huienzhan anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT jinglai anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT yaowang anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT huayou anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT yutinggao novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT liwei novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT liwei novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT seokjinkim novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT liangwang novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT yingzhihe novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT yanfangzheng novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT yanfangzheng novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT lucabertero novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT alessiapellerino novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT paolacassoni novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT lucatamagnone novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT lucatamagnone novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT prochazkakatharinatheresa novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT alexanderdeutsch novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT huienzhan novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT jinglai novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT yaowang novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT huayou novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
_version_ 1721223105231192064
spelling doaj-500e366c639d45f688f61bc4f369c0cd2021-08-03T13:55:17ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-08-011110.3389/fonc.2021.696147696147A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk GroupsYuting Gao0Li Wei1Li Wei2Seok Jin Kim3Liang Wang4Yingzhi He5Yanfang Zheng6Yanfang Zheng7Luca Bertero8Alessia Pellerino9Paola Cassoni10Luca Tamagnone11Luca Tamagnone12Prochazka Katharina Theresa13Alexander Deutsch14Huien Zhan15Jing Lai16Yao Wang17Hua You18Department of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, ChinaDepartment of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, ChinaNHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing Population and Family Planning Science and Technology Research Institute, Chongqing, ChinaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South KoreaDepartment of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaDepartment of Hematology, ZhuJiang Hospital of Southern Medical University, Guangzhou, ChinaDepartment of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, ChinaDepartment of Oncology, ZhuJiang Hospital of Southern Medical University, Guangzhou, ChinaPathology Unit, Department of Medical Sciences, University of Turin, Torino, ItalyDepartment of Neuro-Oncology, University and City of Health and Science Hospital, Torino, ItalyPathology Unit, Department of Medical Sciences, University of Turin, Torino, ItalyUniversità Cattolica del Sacro Cuore, Department of Life Sciences and Public Health, Rome, Italy0Fondazione Policlinico Universitario “A. Gemelli”- IRCCS, Rome, Italy1Clinical Department of Hematology, Medical University of Graz, Graz, Austria1Clinical Department of Hematology, Medical University of Graz, Graz, Austria2Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, China2Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, ChinaDepartment of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, ChinaDepartment of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, ChinaBackgroundPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL.MethodsWe included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort.ResultsBy univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system.ConclusionsIn the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model.https://www.frontiersin.org/articles/10.3389/fonc.2021.696147/fullprimary central nervous system lymphomalactate dehydrogenase-to-lymphocyte ratioprognostic parameterMemorial Sloan Kettering Cancer Center (MSKCC) scoreneutrophil-to-lymphocyte ratio